Chemoprevention of Breast Cancer: Recommendations and Rationale
Open Access
- 2 July 2002
- journal article
- editorial
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 137 (1) , 56-58
- https://doi.org/10.7326/0003-4819-137-1-200207020-00016
Abstract
This statement summarizes the current recommendations of the U.S. Preventive Services Task Force (USPSTF) for chemoprevention of breast cancer. The complete USPSTF recommendation and rationale statement on this topic, including a summary of the supporting evidence, is available through the USPSTF Web site (www.preventiveservices.ahrq.gov), the National Guideline Clearinghouse (www.guideline.gov), and in print through the Agency for Healthcare Research and Quality Publications Clearinghouse (telephone, 800-358-9295; e-mail, ahrqpubs@ahrq.gov). The complete information on which this statement is based, including evidence tables and references, is available in the accompanying article in this issue and in the summary of the evidence and systematic evidence review on the Web sites already mentioned. *For a list of the members of the U.S. Preventive Services Task Force, see the Appendix.Keywords
This publication has 2 references indexed in Scilit:
- Weighing the Risks and Benefits of Tamoxifen Treatment for Preventing Breast CancerJNCI Journal of the National Cancer Institute, 1999
- American Society of Clinical Oncology Technology Assessment on Breast Cancer Risk Reduction Strategies: Tamoxifen and RaloxifeneJournal of Clinical Oncology, 1999